At a glance
The selected record includes rat-derived tendon experiments and three small uncontrolled human reports covering knee pain, bladder symptoms and brief safety observation. Their endpoints and routes differ and should not be pooled into a treatment success rate.
Identity & scope
The literature describes a synthetic 15-amino-acid peptide. The arginine-salt capsule label is retained as a separate product specification; the selected studies do not validate that salt or capsule formulation.
What the research shows
- Chang and colleagues observed migration and stress-survival effects in rat tendon cultures, without a direct proliferation effect in the 2011 experiment.
- The 2021 knee report records perceived pain improvement, not controlled proof of tendon, ligament or cartilage repair.
Critical interpretation
Mechanism is a question, not a clinical conclusion
Migration, cell survival and receptor expression can help explain why a molecule merits investigation. They do not by themselves show that an injured human tendon becomes stronger or that recovery is faster. The two tendon papers ask different experimental questions: absence of a direct proliferation signal in one assay is compatible with altered responsiveness to added growth hormone in another. It would be misleading to compress both into a claim that BPC-157 broadly increases growth hormone or heals injuries. [1] [2]
The human reports need controls and replication
The knee and bladder reports are useful observations, but symptom change after a procedure cannot separate the compound from expectation, natural fluctuation, selection or other care. The tiny intravenous study adds short-term observations in two prior users. Its normal selected measurements are not evidence that uncommon or delayed problems cannot occur. These studies support better trial design, not a general safety declaration. A research programme would need prospective controls, prespecified outcomes, transparent formulation testing and follow-up matched to the harms being investigated. [3] [4] [5]
Separate the compound from the delivery claim
None of these studies is a comparison of the listed arginine-salt capsules with a vial, spray or pen. A format-specific conclusion would require its own composition, stability and exposure evidence. The literature can justify a research question while leaving that commercial specification unvalidated. [1] [4] [5]
Limitations & uncertainties
- The human chart review had no placebo or untreated comparison, variable follow-up and no validated functional assessment.
- Evidence for a peptide does not establish absorption, stability, efficacy or safety of a nasal preparation, capsule, pen or supplied vial.
Open research questions
- Would adequately blinded, controlled human studies demonstrate a clinically meaningful benefit with a fully characterised formulation?
Selected papers & source records
Download bibliography1. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (opens in a new tab)
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). Journal of Applied Physiology. DOI: 10.1152/japplphysiol.00945.2010 (opens in a new tab) · PMID 21030672
- Design & population
- Rat Achilles-tendon explants and cultured tendon fibroblasts.
- What the study found
- Outgrowth, migration and survival under oxidative stress increased; direct proliferation did not. FAK/paxillin phosphorylation changed.
- Limits on interpretation
- Cell and explant endpoints do not measure recovery in people.
2. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts (opens in a new tab)
Chang CH, Tsai WC, Hsu YH, Pang JH (2014). Molecules. DOI: 10.3390/molecules191119066 (opens in a new tab) · PMID 25415472
- Design & population
- Cultured tendon fibroblasts isolated from male rats.
- What the study found
- Growth-hormone-receptor expression increased, and added growth hormone increased proliferation-related measures after BPC-157 pretreatment.
- Limits on interpretation
- A cellular interaction does not establish increased circulating growth hormone or human tissue repair.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (opens in a new tab)
Lee E, Padgett B (2021). Alternative Therapies in Health and Medicine. · PMID 34324435
- Design & population
- Retrospective chart review with telephone follow-up of 16 patients, including 12 receiving BPC-157 alone.
- What the study found
- Eleven of the 12 BPC-157-only recipients reported improvement; one did not.
- Limits on interpretation
- Uncontrolled, unblinded and reliant on recollection. No validated function scale or imaging evidence of structural repair.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
4. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (opens in a new tab)
Lee E, Walker C, Ayadi B (2024). Alternative Therapies in Health and Medicine. · PMID 39325560
- Design & population
- Retrospective clinical-record review of 12 women with bladder pain syndrome after an experimental local procedure.
- What the study found
- Ten reported complete symptom resolution and two reported substantial improvement; no adverse events were reported.
- Limits on interpretation
- No control group or blinded assessment, selected clinic population and a local procedure. These findings cannot establish a causal effect or general safety.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
5. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (opens in a new tab)
Lee E, Burgess K (2025). Alternative Therapies in Health and Medicine. · PMID 40131143
- Design & population
- Uncontrolled three-day observation of two adults who had previously received intravenous BPC-157.
- What the study found
- No reported adverse symptoms or clinically important changes in the selected routine measurements during observation.
- Limits on interpretation
- Two previously exposed volunteers and very brief follow-up cannot establish population safety, rare harms or pharmacokinetics. This is not a human half-life study.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted web discovery of primary PubMed and journal records, following the existing tendon reference and looking for human reports.. Checked 9 November 2026.
Selected tendon mechanisms plus the knee, bladder and intravenous human reports. Publisher or author-hosted full text was consulted for all three human reports.
Not an exhaustive database review or pooled estimate. Targeted exact-title/PMID notice searches did not retrieve a formal correction or retraction for these three human reports; intermittent PubMed retrieval and search-index coverage prevent a comprehensive status clearance.
Recorded search terms
- BPC-157 21030672 Chang growth hormone tendon cells
- site.pubmed.ncbi.nlm.nih.gov BPC 157 human knee pain 2021 Lee Burgess
- BPC 157 retraction 21030672
- Safety of Intravenous Infusion of BPC157 in Humans pdf
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis pdf
- Safety of Intravenous Infusion of BPC157 retracted OR erratum OR correction
- Intra-Articular Injection of BPC 157 retracted OR erratum OR correction
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis retracted OR erratum OR correction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. BPC-157: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/bpc-157.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.